Forus triples valuation to $3bn as Bain backs its AI prescription play

There is a quiet revolution happening in the space between a doctor's pen and a patient's medicine cabinet, and it now carries a $3 billion price tag. Forus, the healthcare technology company building an AI-driven network around prescriptions, has just closed a $150 million Series C round that triples its valuation from its previous funding stage. For those watching African capital flows, this is not just another Silicon Valley software story; it is a signal about where global venture money believes healthcare's most stubborn bottlenecks actually are — and how much it will pay to clear them.

The round was led by Bain Capital Ventures, a firm that has backed Forus since its seed stage, with all existing institutional investors returning. That list is a who's who of venture royalty: Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Vast Ventures and SV Angel. The new financing pushes Forus' total raised past the $300 million mark, a steep climb for a company founded on the unglamorous premise of fixing what happens after a prescription is written. Chief executive Sahir Jaggi says the ambition is now to put the platform into every US doctor's office, but the company's immediate focus is expansion across specialties, care settings and the full arc of treatment journeys.

To understand why this matters beyond America's borders, you must first grasp the problem Forus attacks. In the United States, one in three patients prescribed a high-cost or complex medicine never receives their first dose. The reasons are rarely medical — they are administrative. Insurance rejections, financial assistance paperwork, pharmacy coordination and supply chain snags conspire to delay or kill treatments. Forus deploys AI agents that manage each prescription individually, navigating insurance requirements, enrolling patients in assistance programmes and coordinating with pharmacies. Each prescription gets its own agent, learning from millions of prior cases, so the system becomes smarter with every interaction. The service is free for providers and patients, which explains its rapid adoption: more than a third of US providers in its first specialty now use the platform, and it reaches patients across 85% of residential ZIP codes.

For a reader in Lagos or Nairobi, the relevance here is twofold. First, this validates a thesis that administrative friction — not just drug cost — is the hidden tax on modern healthcare. African health systems often lack the digital backbone to even track prescriptions, let alone automate their fulfilment, but the lesson is universal: the gap between diagnosis and treatment is where patients are lost. Second, Forus' business model, which monetises relationships with biopharma companies rather than charging doctors, shows how infrastructure platforms can align incentives across an entire value chain. The company already works with nine of the world's 15 largest biopharma firms and several fast-growing biotechs, giving it a privileged view of where drugs fail to reach patients.

What makes this round particularly notable is the valuation leap itself. Tripling in value between funding rounds, during a period when many late-stage tech companies have seen markdowns, suggests investors are treating healthcare automation as a rare growth pocket. Bain Capital Ventures' continued backing from seed to Series C signals conviction that Forus is becoming essential infrastructure, not a feature bolted onto an existing system. The broader trend is clear: AI companies are moving from flashy diagnostic tools to the unglamorous work of eliminating administrative waste, which in the US alone accounts for hundreds of billions in annual spending.

Looking ahead, Forus plans to extend its AI agents beyond prescription fulfilment into the broader treatment journey, including drug development feedback loops. By connecting real-world treatment experiences back to biopharma companies, it hopes to shorten the cycle between laboratory breakthroughs and patient bedsides. For Africa's emerging health-tech scene, the takeaway is strategic: the next wave of healthcare value may not come from inventing new medicines, but from building the intelligent logistics that get existing ones to the people who need them. Forus has shown that investors will pay a premium for that coordination layer — a lesson that transcends geography.